From the Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
From the Department of Pharmacy, King Abdullah bin Abdulaziz University Hospital, Riyadh, Saudi Arabia.
Ann Saudi Med. 2022 Jul-Aug;42(4):223-228. doi: 10.5144/0256-4947.2022.223. Epub 2022 Aug 4.
The rate of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection and immunogenicity of a single dose of ChAdOx1 vaccine at 16 weeks post-vaccination among young and healthy participants remains unclear in Saudi Arabia.
Assess the rate of subsequent infection and immunogenicity of a single dose of ChAdOx1 vaccine at 16 weeks post-vaccination in a sample of healthy and young participants.
Cross-sectional study SETTING: Academic teaching hospital in Riyadh, Saudi Arabia SUBJECTS AND METHODS: Healthy participants 18-50 years of age, who received one dose of ChAdOx1 vaccine and had no history of SARS CoV-2 infection were recruited, and blood samples were obtained 16 weeks after vaccination to assess immunogenicity using a commercially available kit.
The rate of SARS-CoV-2 infection within 16 weeks post-vaccination.
385 participants with median (IQR) age of 34 (29-38) years.
Eleven (2.8%) participants acquired polymerase chain reaction (PCR)-confirmed infection within 16 weeks after a single dose of ChAdOx1 vaccine (mean [SD] 42.5 [28] days post-vaccination). No hospital or intensive care unit admissions occurred among the subjects in this sample. Females were significantly over-represented in PCR-confirmed cases of SARS-CoV-2 infection, with 10 of 11 infections occurring in females (=.006). Antibody response against anti-spike IgG were detectable in 92.7% of subjects at 16 weeks' post-vaccination. The median anti-spike IgG level after vaccination was 273.1 (IQR 107-1052 AU/mL). However, the anti-nucleocapsid IgG antibody demonstrated a sensitivity of only 20%.
A single dose of ChAdOx1 vaccine in healthy and young individuals was associated with a low, single-digit rate of PCR-confirmed infection, most of which were mild.
Small sample size and single-center.
None.
在沙特阿拉伯，16 周时，腺病毒载体 ChAdOx1 疫苗接种一剂后，年轻人和健康参与者中严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染和免疫原性的发生率仍不清楚。
评估在健康年轻参与者样本中，接种一剂 ChAdOx1 疫苗后 16 周的后续感染和免疫原性。
横断面研究
沙特阿拉伯利雅得的学术教学医院
招募了年龄在 18-50 岁之间，接受过一剂 ChAdOx1 疫苗接种且无 SARS-CoV-2 感染史的健康参与者，并在接种疫苗后 16 周采集血样，使用市售试剂盒评估免疫原性。
接种后 16 周内 SARS-CoV-2 感染的发生率。
385 名参与者，中位数（IQR）年龄为 34（29-38）岁。
在接种一剂 ChAdOx1 疫苗后 16 周内，有 11 名（2.8%）参与者经聚合酶链反应（PCR）确认为感染（平均[SD]接种后 42.5[28]天）。在该样本中，受试者中未发生医院或重症监护病房住院。PCR 确认为 SARS-CoV-2 感染的病例中，女性明显过多，11 例感染中有 10 例发生在女性中（=.006）。接种后 16 周时，92.7%的受试者可检测到针对抗刺突 IgG 的抗体反应。接种后，抗刺突 IgG 水平中位数为 273.1（IQR 107-1052 AU/mL）。但是，抗核衣壳 IgG 抗体的敏感性仅为 20%。
在健康年轻个体中接种一剂 ChAdOx1 疫苗，与 PCR 确诊感染的低发生率（个位数）相关，其中大多数为轻症。
样本量小且为单中心。
无。
